Raul Flores, MD
Advanced Heart Failure and Transplant Cardiology · Morristown, NJNPI 1376938589
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,732 of the $10,758 with a category attached, or 81.2%. 33 manufacturers reported payments, led by Abbott at 33.3% of the total.
Across 303 payments — averaging $35.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- AOP Health US, LLC$2K
- Abiomed$566
- Merck$518
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$438
- Alnylam Pharmaceuticals Inc.$400
- plus $4K from 27 others
What the payments were for
- Travel & lodging$1,95018%
- Food & beverage$8,73281%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 34 | $3,585 |
| AOP Health US, LLC | 2 | $1,519 |
| Abiomed | 6 | $566 |
| Merck | 28 | $518 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $438 |
| Alnylam Pharmaceuticals Inc. | 23 | $400 |
| Pfizer | 27 | $387 |
| Boehringer Ingelheim | 22 | $359 |
| AstraZeneca | 19 | $356 |
| Actelion Pharmaceuticals US, Inc. | 19 | $305 |
| Bayer | 16 | $251 |
| Daxor Corporation | 4 | $245 |
| Novartis | 16 | $245 |
| Boston Scientific | 4 | $219 |
| E.r. Squibb & Sons, L.L.C. | 11 | $197 |
| United Therapeutics Corporation | 10 | $167 |
| Amgen | 10 | $152 |
| Impulse Dynamics (USA) Inc. | 1 | $141 |
| Lexicon Pharmaceuticals, Inc. | 8 | $140 |
| Scpharmaceuticals Inc. | 4 | $78 |
| Bridgebio Pharma, Inc. | 4 | $76 |
| Baxter Healthcare | 2 | $74 |
| Endotronix, Inc. | 2 | $57 |
| Nuwellis, Inc. | 2 | $51 |
| Argon Medical Devices, Inc. | 2 | $46 |
| Cvrx, Inc. | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Masimo Corporation | 1 | $25 |
| Astellas Pharma US Inc | 1 | $19 |
| Sensible Medical Innovations Inc | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Stryker | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rapiblyk$3,037
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,589
- CARDIOMEMS$330
- OPTIMIZER$282
- Impella$242
- AVVIGO Guidance System$144
- BVA-100$124
How this compares
$10,758 in reported general payments places this provider in the 60th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
See all advanced heart failure and transplant cardiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 155 | $3,964,636 |
| VyndaqelTafamidis Meglumine | 11 | $245,852 |
| EntrestoSacubitril/Valsartan | 63 | $84,776 |
| JardianceEmpagliflozin | 47 | $61,879 |
| FarxigaDapagliflozin Propanediol | 40 | $34,940 |
| EliquisApixaban | 18 | $19,404 |
| Sildenafil Citrate | 32 | $7,172 |
| Eplerenone | 18 | $1,790 |
| Spironolactone | 128 | $1,060 |
| Torsemide | 34 | $740 |
| Metoprolol Succinate | 28 | $605 |
| Furosemide | 33 | $81 |
| Carvedilol | 17 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $387 | $4,229,893184 claims |
| NovartisEntresto | $245 | $84,77663 claims |
| Boehringer IngelheimJardiance | $359 | $61,87947 claims |
| AstraZenecaFarxiga | $356 | $34,94040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
Other advanced heart failure and transplant cardiology in Morristown
- Abhishek SinghMorristown$283K
- Saad AhmadMorristown$74K
- Mark ZuckerMorristown$44K
- Kanika ModyHackensack$107K
- Kulpreet BarnBarnegat$92K
- Robert MohapatraSewell$84K
- Saurabh KapoorEnglewood$27K
- Ketan GalaCherry Hill$18K
- Ahmed SeliemCamden$8K
- Eman RashedNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.